GLP-1 Weight Loss Maintenance Guide

The STEP 4 trial was a landmark extension of the STEP 1 semaglutide trial. Patients who had lost an average of 17% of their body weight over 68 weeks on semaglutide were then randomized to either continue semaglutide or switch to placebo. Within one year of stopping, the placebo group had regained approximately two-thirds of their lost weight — about 11.6% of their original body weight, at a rate of roughly 1-2 lbs per month.

This is not a failure of willpower — it is the body defending its weight set point, a phenomenon documented for decades in obesity research. The body has powerful compensatory mechanisms to restore weight after loss: appetite hormones (ghrelin) increase, satiety hormones (leptin, PYY) decrease, metabolic rate slows (adaptive thermogenesis), and the brain's reward circuits increase the motivational salience of food. GLP-1 medications suppress all of these counter-regulatory responses; when the drug stops, they resume in full force.

This biology is increasingly reshaping how physicians think about GLP-1 medications: not as a temporary intervention to use until you lose the weight and then stop, but as a chronic treatment for a chronic condition — exactly as antihypertensives are used for high blood pressure. No one expects to stop their blood pressure medication after their numbers normalize and maintain the benefit without the drug. Obesity is no different from this physiological standpoint.

Wegovy 2.4mg weekly is FDA-approved as a chronic weight management medication with no defined stopping point. Continuing at the full dose maintains the maximum weight loss benefit and the fullest suppression of appetite and weight-regain signals. For patients who have reached their goal weight, some physicians trial a step-down to 1.7mg or 1mg to reduce cost and side effect exposure — weight is monitored closely and dose restored if regain occurs.

Ozempic (prescribed off-label for weight loss at doses up to 2mg) can similarly be continued long-term. The key is that continuous GLP-1 exposure is required to maintain the hormonal environment that supports the lower body weight. There is no “training” of the body to maintain weight on its own — the drug must be present to continuously suppress the compensatory weight-regain drive.

The SURMOUNT-4 trial specifically studied maintenance dosing for tirzepatide. Patients who had lost weight on tirzepatide were randomized to continue at a maintenance dose or switch to placebo. Those who continued tirzepatide (even at doses lower than their maximum) maintained over 80% of their weight loss, while the placebo group regained a large portion. This is the strongest evidence to date that continuing at a lower maintenance dose is a viable long-term strategy.

Zepbound (tirzepatide for weight management) is available at doses from 2.5mg to 15mg weekly. A maintenance dose of 5mg or 7.5mg after reaching goal on 10mg or 15mg may be sufficient for many patients — with cost savings and often better tolerability — while still maintaining meaningful weight loss vs placebo. This should be personalized with your prescriber.

Semaglutide (Ozempic / Wegovy) Maintenance: Wegovy 2.4mg weekly is FDA-approved as a chronic weight management medication with no defined stopping point. Continuing at the full dose maintains the maximum weight loss benefit and the fullest suppression of appetite and weight-regain signals. For patients who have reached their goal weight, some physicians trial a step-down to 1.7mg or 1mg to reduce cost and side effect exposure — weight is monitored closely and dose restored if regain occurs. Ozempic (prescribed off-label for weight loss at doses up to 2mg) can similarly be continued long-term. The key is that continuous GLP-1 exposure is required to maintain the hormonal environment that supports the lower body weight. There is no “training” of the body to maintain weight on its own — the drug must be present to continuously suppress the compensatory weight-regain drive.

Tirzepatide (Mounjaro / Zepbound) Maintenance: The SURMOUNT-4 trial specifically studied maintenance dosing for tirzepatide. Patients who had lost weight on tirzepatide were randomized to continue at a maintenance dose or switch to placebo. Those who continued tirzepatide (even at doses lower than their maximum) maintained over 80% of their weight loss, while the placebo group regained a large portion. This is the strongest evidence to date that continuing at a lower maintenance dose is a viable long-term strategy. Zepbound (tirzepatide for weight management) is available at doses from 2.5mg to 15mg weekly. A maintenance dose of 5mg or 7.5mg after reaching goal on 10mg or 15mg may be sufficient for many patients — with cost savings and often better tolerability — while still maintaining meaningful weight loss vs placebo. This should be personalized with your prescriber.

Sometimes stopping GLP-1 medication is necessary — due to cost, side effects, pregnancy planning, surgery, or personal choice. If you are planning to stop, these strategies give you the best chance of sustaining your results. The goal is to build as much of a metabolic and behavioral buffer as possible before stopping, so the compensatory weight-regain response has less momentum to overcome.

Research on long-term weight maintenance consistently identifies the same cluster of behaviors in people who successfully maintain significant weight loss. These are evidence-based priorities for the GLP-1 maintenance phase, whether you are continuing medication or transitioning off it.